Network Pharmacology Analysis on the Mechanism of Huangqi Sijunzi Decoction in Treating Cancer-Related Fatigue

Yixin Cui, Haiming Wang, Decai Wang, Jiwei Mi, Gege Chen, Fagen Li, Yujia Wang, and Yin Zhang

1Department of Traditional Chinese Medicine and Acupuncture, The First Medical Center, General Hospital of Chinese PLA, Beijing 100853, China
2The Second Outpatient Department of Aerospace Center Hospital, Beijing 100049, China
3Department of General Practice, The Central People’s Hospital, Zhanjiang, Guangdong 524037, China
4Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050000, China

Correspondence should be addressed to Yin Zhang; wenxiaoxin2021@126.com

Yixin Cui and Haiming Wang contributed equally to this work.

Received 1 September 2021; Accepted 18 October 2021; Published 18 November 2021

Objective. This study aimed to determine the active ingredients of Huangqi Sijunzi Decoction (HQSJZD) and the targets in treating cancer-related fatigue (CRF) so as to investigate the treatment mechanism of HQSJZD for CRF. Methods. This study adopted the method of network pharmacology. The active ingredients and targets of HQSJZD were retrieved, and the targets of HQSJZD in treating CRF were obtained using a Venn diagram. Next, a protein-protein interaction (PPI) network was constructed using the String database. The core targets of HQSJZD in treating CRF were identified through topological analysis, and functional annotation analysis and pathway enrichment analysis were carried out. Subsequently, a compound-disease-target regulatory network was constructed using Cytoscape 3.8.0 software. Results. A total of 250 targets of HQSJZD ingredients, 1447 CRF-related genes, and 144 common targets were obtained. Through topological analysis, 61 core targets were screened. Bioinformatics annotation of these genes identified 2366 gene ontology (GO) terms and 172 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Conclusion. The active ingredients in HQSJZD, that is, quercetin, luteolin, kaempferol, and naringenin, may act on AKT1, IL-6, VEGFA, MAPK3, CASP3, JUN, and EGFR to regulate the PI3K-Akt, TNF, and IL-17 signaling pathways, thereby suppressing inflammatory response, tumor gene expression, and tumor angiogenesis to treat CRF. This study investigated the pharmacological basis and mechanism of HQSJZD in the treatment of CRF using systematic pharmacology, which provides an important reference for further elucidation of the anti-CRF mechanism and clinical applications of HQSJZD, and also provides a method protocol for similar studies in the future.

1. Introduction

Cancer-related fatigue (CRF) refers to the painful, continuous, and subjective feeling of fatigue or exhaustion resulting from malignant tumor or tumor-related treatments, which is accompanied by symptoms such as limb heaviness, insomnia or somnolence, difficulty in activities, and abnormal emotional responses, but is not related to the amount of exercise [1]. CRF has an incidence rate in tumor patients of as high as 75% [2], and patients with CRF demonstrate higher degrees of fatigue than ordinary people, a longer course of disease, no remission after resting, and a greater propensity for negative emotions, which seriously affect the quality of life of the patients. It is currently well known by scholars worldwide that the production of cytokines, the abnormal accumulation of muscle metabolites, and mitochondrial dysfunction are involved in CRF [3]. Cytokines released by tumor cells, such as IL-2, IL-6, and tumor necrosis factor (TNF), not only affect the metabolism of normal cells but also promote tumor cell growth, resulting...
in impaired body functions and the occurrence of fatigue symptoms [4]. Peripheral inflammatory cytokines can enter the brain via various paths, and cytokines like IL-6 and TNF may affect the hypothalamicpituitary-adrenal (HPA) axis and suppress cortisol synthesis and release, thereby aggravating fatigue symptoms [5]. After chemotherapy or radiotherapy, the mitochondrial structure and function are destroyed, which can also aggravate fatigue [6]. According to the NCCN Cancer-Related Fatigue (CRF) guidelines, CRF is mainly treated with drugs such as psychostimulants or those for improving sleep dysfunction; nondrug treatments like social-psycho intervention and acupuncture, however, do not provide satisfactory effects.

According to traditional Chinese medicine (TCM), CRF belongs to the "consumptive disease" category. When cancer toxins have invaded the body for a prolonged period, the blood and Qi of the patients are impaired, which may lead to the impairment of kidney functions and the failure of the five organs, resulting in the occurrence of CRF. Moreover, surgery, radiotherapy, and chemotherapy aggravate blood and Qi impairment, thereby exacerbating fatigue symptoms. Therefore, the pathogenesis of CRF in TCM involves the impairment of the five organs and Qi/blood deficiency. In this regard, CRF is mainly treated by strengthening the body's resistance and tonifying the body to compensate for the deficiency.

In recent studies, the therapeutic effects of Huangqi Sijunzi Decoction (HQSJZD) on treating CRF have been recognized by numerous doctors. HQSJZD is modified from Sijunzi Decoction, with the addition of Astragalus, which has Qi-tonifying, blood-replenishing, body-resistance-enhancing, and deficiency-tonifying effects. The Sijunzi Decoction consists of ginseng (which is often replaced by Codonopsis pilosula owing to the rareness of ginseng), Atractylodes, poria cocos, and radix glycyrrhizae. This is a classical and representative TCM preparation for Qi tonifying. The addition of Astragalus further enhances the Qi- and spleen-tonifying, body-resistance-strengthening, and consolidating effects. Pharmacological research [7] has confirmed that Sijunzi Decoction can accelerate the recovery of NK cell and K cell activities that are suppressed after chemotherapy and enhance granulocyte, monocyte, and bone marrow hematopoietic functions. Moreover, the addition of Astragalus has been found to improve RNA synthesis in the liver and enhance the energy metabolic rate of mice with spleen deficiency and to reduce mitochondrial injury and improve energy metabolic disorder [8]. HQSJZD has been proved in clinical practice to correct anemia, improve immune function, and mitigate energy metabolic disorder, thus relieving CRF symptoms [8]. However, the molecular mechanism of HQSJZD in CRF treatment remains unclear, which limits its promotion and development.

Network pharmacology can systematically analyze the interaction network of drug components, protein targets, diseases, and genes and is effective for establishing a "compound-protein/gene-disease" network in a highthroughput manner [9, 10]. This approach is powerful for the analysis of TCM preparations. A number of researchers have applied network pharmacology to study the mechanism of TCM in various diseases [11–14]. This study screened the active ingredients of HQSJZD and the human targets of these ingredients as well as CRF-related genes. Network pharmacology was used to explore the relationship between the active ingredients of HQSJZD and CRF targets and the mechanism of HQSJZD treatment of CRF to provide reference for further elucidation of the anti-CRF mechanism and clinical applications of HQSJZD.

2. Methods

The study strategy is illustrated in Figure 1.

2.1. Screening for the Targets of HQSJZD Ingredients. The components of HQSJZD, Atractylodes, Codonopsis pilosula, Poria cocos, radix glycyrrhiza, and Astragalus were searched in the TCMSP database [15] (https://tcmspw.com/tcmsp.php), with oral bioavailability (OB) ≥30% and drug likeness (DL) ≥0.18 used as screening criteria to screen for targets of corresponding ingredients. Next, the uniprot database (https://www.uniprot.org/) [16] was used for target correction, with species restricted to "Homo sapiens," and the target proteins were transformed into corresponding genes.

2.2. Screening of CRF-Related Genes. Using "cancer-related fatigue" as keyword, human genes were screened in the GeneCards database [17] (https://www.genecards.org), NCBI database [18] (https://www.ncbi.nlm.nih.gov), and OMIM database [19] (https://www.omim.org) for CRD-related genes. Targets in the GeneCards database were screened according to the median value, so more related targets were obtained.

2.3. Prediction of Potential Targets of HQSJZD in Treating CRF. The Venn diagram generation software Venny 2.1 was used to obtain the potential targets of HQSJZD in treating CRF from targets corresponding to the active ingredients of HQSJZD and the CRF-related targets.

2.4. Construction of the PPI Network and Topological Analysis. The PPI network was constructed using the String database [20] (https://string-db.org/cgi/input.pl), with the common drug-disease targets screened. The biological species was set to "Homo sapiens," and the minimum interaction score was set at medium confidence (0.400). The NetworkAnalyzer tool of the Cystoscape 3.8.0 software [21] was used for topological analysis of the PPI network. Genes were sorted based on degree values, and genes with scores greater than the mean value were selected as the core targets.

2.5. Screening of Key Active Ingredients. To better understand the complicated interactions among drug components, disease, and corresponding targets, a component-disease-target network was constructed based on the screened drug ingredients, disease, and targets using the Cystoscape 3.8.0 software for topological analysis. Drug ingredients were...
2.6. GO Functional Enrichment and KEGG Pathway Enrichment Analyses. GO enrichment analysis was performed on the common drug-disease targets. Using the String database, terms with a corrected $P$ value $<0.05$ were selected. Next, the clusterProfiler, enrichplot, and ggplot2 packages of the R 4.0.3 software were employed to plot the bubble chart. The common drug-disease targets were also applied to KEGG pathway enrichment analysis, pathways with corrected $P$ value $<0.05$ were selected, and the top 20 pathways were visualized.

2.7. Construction of the Component-Disease Pathway-Target Network. Drug components, the top 20 KEGG pathways, and core targets were imported into the Cytoscape 3.8.0 software to construct the component-disease pathway-target network.

3. Results

3.1. Screening of the Potential Targets of HQSJZD in Treating CRF. The active ingredients of HQSJZD were retrieved from the TCMSP database, including 20 Astragalus ingredients, 21 Codonopsis pilosula ingredients, 7 Atractylodes ingredients, 15 Poria cocos ingredients, and 93 radix glycyrrhizae ingredients. Moreover, the targets of these active ingredients were also obtained, including 20 targets of Astragalus ingredients, 106 targets of Codonopsis pilosula ingredients, 16 targets of Atractylodes ingredients, 23 targets of Poria cocos ingredients, and 225 targets of radix glycyrrhizae ingredients. Finally, a total of 250 targets were obtained after eliminating duplicates.

A total of 1446 CRF-related genes were obtained after searching the GeneCards database, 13 were obtained from the NCBI database, and 2 were obtained from the OMIM database. After eliminating duplicated genes, 1447 CRF-related genes were retrieved. The screened drug targets and disease targets were intersected to obtain 144 common targets between HQSJZD and CRF (Figure 2), which were used as the potential targets of HQSJZD in treating CRF in subsequent network construction and pathway enrichment analysis.

3.2. Core Targets of HQSJZD in Treating CRF. In the PPI network constructed using the 144 common targets (Figure 3), the color and size of the nodes were plotted based on the degree value; a bigger node and deeper color indicate a greater degree value. A total of 3074 edges, representing protein interactions, were established. The edge thickness represents the edge betweenness, and a thicker line indicates a stronger relationship between the two targets. The average degree value of the PPI network is 42.7. Topological analysis of the PPI networks identified 61 genes with scores greater than the average as the core targets. The top 20 genes were plotted (Figure 4), with the X-coordinate being the degree of each gene; the greater the value, the more important the role the gene plays in the
**Figure 2:** Venn diagram of the targets of the active ingredients of HQSJZD and the CRF-related targets.

**Figure 3:** PPI network of the common targets of HQSJZD and CRF.
network. Therefore, the AKT1, IL6, VEGFA, MAPK3, CASP3, JUN, EGFR, MAPK1, and MYC genes may play the most important roles in the HQSJZD treatment of CRF.

3.3. Screening of Key Components. Topological analysis of the component-disease-target network constructed using the Cystoscape 3.8.0 software identified the key components of HQSHZD and ranked them based on degree values; a higher value represents greater importance. Components with a value greater than 10 were chosen for subsequent analysis (Table 1). The component with the highest value was quercetin, followed by luteolin, kaempferol, naringenin, formononetin, and isorhamnetin.

3.4. GO Enrichment Analysis. The 144 HQSJZD-CRF common targets were subjected to GO enrichment analysis. A total of 2332 BP terms ($P < 0.01$), 6 CC terms, and 27 MF terms were retrieved. The top 10 GO terms of each category were plotted in the bubble chart (Figure 5). The top BP terms are mainly involved in oxidative stress response, cellular response to chemical stress, response to bacterial molecules, cellular response to oxidative stress, reactive oxygen species metabolic process, regulation of the apoptotic signaling pathway, epithelial cell proliferation, regulation of inflammatory response, regulation of DAN binding transcription factor activity, response to hypoxia, and negative regulation of the apoptotic signaling pathway. The common targets were mainly enriched in six CC terms, including membrane raft, membrane microdomain, membrane region-protein kinase complex, cyclin-dependent protein kinase holoenzyme complex, serine/threonine protein kinase complex, and vesicle lumen. The enriched MF terms mainly include DNA binding transcription factor binding, RNA-polymerase-specific DNA binding transcription factor binding, nuclear receptor activity, ligand activation, transcription factor activity, phosphatase binding-cytokine receptor binding, heme binding tetrapyrrole binding, cytokine activity, and protein phosphatase binding.

3.5. KEGG Pathway Analysis. The 144 common targets were significantly enriched into 172 pathways ($P < 0.05$). The top 20 pathways are shown in Figure 6. Pathways not related to

Table 1: Top active ingredients of HQSJZD identified in the component-target network.

| MOL ID    | Name                               | Degree |
|-----------|------------------------------------|--------|
| MOL000098 | Quercetin                          | 106    |
| MOL000006 | Luteolin                           | 46     |
| MOL000422 | Kaempferol                         | 36     |
| MOL004328 | Naringenin                         | 24     |
| MOL000392 | Formononetin                       | 21     |
| MOL000354 | Isorhamnetin                       | 20     |
| MOL003896 | 7-Methoxy-2-methyl isoflavone      | 20     |
| MOL000497 | Licochalcone                       | 19     |
response to oxidative stress
cellular response to chemical stress
response to lipopolysaccharide
response to molecule of bacterial origin
cellular response to oxidative stress
response to drug
reactive oxygen species metabolic process
response to metal ion
response to reactive oxygen species
membrane raft
membrane microdomain
membrane region
vesicle lumen
transcription regulator complex
organelle outer membrane
outer membrane
protein kinase complex
serine/threonine protein kinase complex
cyclin-dependent protein kinase holoenzyme complex
DNA-binding transcription factor binding
RNA polymerase II-specific DNA-binding transcription factor binding
cytokine receptor binding
cytokine activity
heme binding
tetrapyrrole binding
protein phosphatase binding
nuclear receptor activity
transcription factor activity

Figure 5: Top GO enriched terms of HQSJZD in treating CRF. The X-coordinate indicates the number of enriched genes, and the color of the dot represents the $P$ value of the corresponding term. A bigger dot indicates that more genes are enriched.

Lipid and atherosclerosis
PI3K-Akt signaling pathway
Hepatitis B
Kaposi sarcoma-associated herpesvirus infection
Human cytomegalovirus infection
AGE-RAGE signaling pathway in diabetic complications
Hepatitis C
Prostate cancer
Fluid shear stress and atherosclerosis
Cellular senescence
IL-17 signaling pathway
TNF signaling pathway
Pancreatic cancer
Small cell lung cancer
Endocrine resistance
Toxoplasmosis
Non-small cell lung cancer
Chagas disease
Bladder cancer
EGFR tyrosine kinase inhibitor resistance

Figure 6: Top KEGG enriched pathways of HQSJZD in treating CRF. A bigger dot indicates that more genes are enriched in that pathway, and a dot with a darker red color represents a smaller $P$ value.
CRF, such as the “AGE-RAGE signaling pathway in diabetic complications,” were excluded. Finally, 9 pathways with the smallest P values were selected: phosphatidylinositol 3 kinase/protein kinase B (PI3K-Akt) signaling pathways, prostate cancer, bladder cancer, pancreatic cancer, IL-17 signaling pathway, non-small cell lung cancer, TNF signaling pathway, and small cell lung cancer.

3.6. Construction of the Ingredient-Disease Pathway-Target Network. The ingredient-disease pathway-target network was constructed using Cytoscape3.8.0 software (Figure 7). The network contains 5 drugs, 114 active ingredients (ingredients not directly connected to targets were eliminated), 144 CRF-related disease targets (free protein spots were eliminated), and 20 CRF target-related pathways. Among the active ingredients, quercetin had the highest number of connected edges, followed by luteolin, kaempferol, naringenin, forsythosetin, and isorhamnetin. Among the potential targets, AKT1, IL6, VEGFA, and MAPK3 had relatively more connected edges. Among the pathways, the PI3K-Akt signaling pathway, prostate cancer, bladder cancer, pancreatic cancer, IL-17 signaling pathway, non-small cell lung cancer, TNF signaling pathway, and small cell lung cancer showed more connections with the potential targets.

4. Analysis

4.1. Active Ingredients of HQSJZD in Treating CRF. In this study, 144 active ingredients of HQSJZD in treating CRF were obtained; the most promising ones were quercetin, luteolin, kaempferol, naringenin, forsythosetin, and isorhamnetin. All of them are flavonoids with pharmacological activities such as enzyme regulation, blood circulation improvement, apoptosis regulation, and stem cell signal transduction regulation. Therefore, they have anti-inflammatory, antioxidant, and antitumor effects [22]. Modern pharmacological studies have found that quercetin can eliminate oxygen free radicals to maintain oxidative balance [23], reduce the secretion of inflammatory factors [24], and enhance body functions. Moreover, quercetin has been shown to suppress the PI3K/Akt/mTOR pathway in breast cancer stem cells [25], induce apoptosis, reduce the phosphorylation of IKKβ and 1xβ, and suppress the invasion and progression of malignant tumor cells [26]. Therefore, quercetin has antitumor effects through various pathways [27] and is conducive to relieving CRF. Luteolin can modulate cell signaling pathways, suppress macrophage phosphorylation, reduce NF-kB activity, inhibit lipopolysaccharide- (LPS-) induced production of cytokines like IL-6 and TNF-α by macrophages, and inhibit cancer cell invasion by controlling tumor cell growth factor production and regulating kinase activities [28]. In addition, it can arrest cell cycle progression to suppress tumor cell growth [28] and induce apoptosis through inhibiting AKT activation, thereby increasing P53/bax/cleaved-caspase3 expression and decreasing bcl-2 expression [29]. It has been reported that luteolin can induce changes in cancer cell mitochondrial membrane structure to increase the membrane permeability, resulting in the release of cytochrome C and apoptosis-inducing factor (AIF), which promote cancer cell apoptosis [30]. Kaempferol can down-regulate the PI3K/Akt/mTOR signaling pathway and induce cell autophagy to suppress the proliferation and induce apoptosis of human colorectal cancer RKO cells [31]. Isorhamnetin can reduce mTOR phosphorylation level to suppress tumor cell proliferation and migration [32]. Naringenin has antioxidant activity to relieve oxidative stress, suppresses the production of inflammatory mediators [33], and reduces Bcl-2 expression to improve mitochondrial function and decrease tumor cell apoptosis, thus achieving antitumor effects [34]. Therefore, we speculate that the active ingredients of HQSJZD in treating CRF are mainly flavonoids, which exert their functions through resisting oxidative stress, suppressing inflammatory cytokines, and inhibiting AKT activation.

4.2. Key Targets of HQSJZD in Treating CRF. In our analysis, the degree values of the targets, AKT1, IL6, VEGFA, MAPK3, CASP3, JUN, EGFR, MAPK1, and MYC, were greater than 90, suggesting that they are important core targets with great biological importance and close involvement in the treatment of CRF. AKT1 is a serine/threonine protein kinase and the key member of the PI3K pathway. Activated AKT1 can activate or suppress a series of downstream effectors, thus participating in the regulation of multiple biological processes, such as cell metabolism, proliferation, differentiation, apoptosis, and migration [35]. Research suggests that, during tumor cell metastasis, the lack of original matrix support is disadvantageous to tumor cell survival [36]. AKT1 can enhance the adaptability of tumor cells to the environment and promote tumor cell migration and colonization and thus is closely related to the high invasion of tumor cells [37]. Multiple clinical studies have shown that flavonoid monomers of Chinese traditional herbs can control tumor gene expression, induce apoptosis, promote cell autophagy, inhibit cell proliferation, and suppress tumor angiogenesis through regulating the PI3K/Akt signaling pathway to achieve antitumor effects [38]. Therefore, combined with previous results, AKT1 can be considered as the core target of HQSJZD, with great importance in treating CRF. Mitogen-activated protein kinase (MAPK) is also a serine/threonine protein kinase, and its kinase activity can be activated by cytokines, neurotransmitters, and hormones. Activated MAPK can phosphorylate multiple substrates, including transcription factors, cytoskeletal proteins, and enzymes, to regulate numerous cellular physiological processes. Moreover, it plays an important role in mediating inflammatory response and cytokine production [39]. c-JUN is expressed at a low level in normal cells but is abnormally highly expressed after stimulation, and it forms AP-1 with c-Fos, regulating cell differentiation, proliferation, and apoptosis [40]. VEGF participates in the pathogenesis and progression of numerous angiogenesis-dependent diseases, including cancers, certain inflammatory diseases, and diabetic retinopathy.

4.3. Pathways of HQSJZD in Treating CRF. GO functional enrichment analysis and KEGG pathway enrichment analysis identified important functional terms and pathways that...
are closely related to HQSJZD and CRF targets, and further construction of the ingredient-disease pathway-target network established the connections between drug ingredients and pathways and revealed the molecular mechanisms of HQSJZD in treating CRD. The PI3K-Akt signaling pathway, TNF signaling pathway, and IL-17 signaling pathway were among the top pathways identified in KEGG analysis. The PI3K-Akt pathway plays an important role in tumor cell differentiation and proliferation in prostate cancer and ovarian cancer. Quercetin, the main active ingredient of HQSJZD, can suppress the overexpression of oncogene PTEN, downregulate PIP3 expression, inhibit AKT activity, and block the activation of the PI3K/Akt pathway to regulate tumor progression [41–43] and improve fatigue symptoms. Luteolin, another major ingredient, also downregulates the expression of P-PI3K, p-AKT, and AKT-1 proteins to suppress the tumorigenesis and progression of lung cancer [44]. The persistent activation of the TNF signaling pathway will lead to uncontrolled cell growth, suppress cell apoptosis, and promote tumor metastasis and angiogenesis [45]. The IL-17 signaling pathway is a classical important pathway related to immune responses, apoptosis, and tumorigenesis [46]. Animal experiments have shown that the main active ingredients of HQSJZD, that is, quercetin, luteolin, and kaempferol, can reduce the expression of TNF-α and IL-17 [47], thus improving the tumor microenvironment to effectively relieve CRF. Moreover, it has been revealed by KEGG pathway enrichment analysis that HQSJZD acts on EGFR, MMPs, and ERBB2 to improve bladder cancer-related fatigue and on EGFR, MET, ERBB2, and PI3K-Akt to improve non-small cell lung cancer-related fatigue. Thus, CRF caused by prostate cancer, bladder cancer, pancreatic cancer, and small cell lung cancer can be improved via the PI3K-Akt, TNF, and IL-17 signaling pathways, especially the PI3K-Akt pathway.

In conclusion, the active ingredients of HQSJZD, that is, quercetin, luteolin, kaempferol, and naringenin, may act on multiple targets like AKT1, IL6, VEGFA, MAPK3, CASP3, JUN, and EGFR and regulate multiple signaling pathways like PI3K-Akt, TNF, and IL-17 to suppress inflammatory responses, tumor gene expression, and tumor angiogenesis, thereby achieving the treatment of CRF. This study employed the method of network pharmacology and clearly revealed the "multicomponent, multitarget, and multipathway" mechanism of HQSJZD in treating CRF through network construction. Considering the limitation of network pharmacology, experimental studies are required to further analyze and validate the mechanism of HQSJZD in treating CRF identified in this study.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] X. D. Xie and X. Y. Zhang, “The latest advances in cancer-related fatigue-NCCN (2018 edition) Cancer-related fatigue guide interpretation,” Chinese Journal of Clinical Oncology, vol. 16, pp. 817–820, 2018.
[2] M. F. Wang and W. X. Yao, “A longitudinal study on cancer-related fatigue in breast cancer patients during the comprehensive treatment period,” Chinese Journal of Modern Nursing, vol. 23, no. 4, pp. 466–470, 2017.
[3] M. Y. Hu, X. W. Ye, and W. W. Zhou, “Progresses in cancer-related fatigue and its treatment,” Journal of New Chinese Medicine, vol. 52, no. 16, pp. 21–26, 2020.
[4] J. Y. Lu, M. Zhang, H. L. Jin et al., “Research progress on the genesis and development of lung cancer resulting from the environmental carcinogen-induced chronic inflammation,” Advances in Biochemistry and Biophysics, vol. 1, pp. 41–51, 2014.
[5] L. N. Saligan, K. Olson, K. Olson et al., “The biology of cancer-related fatigue: a review of the literature,” Supportive Care in Cancer, vol. 23, no. 8, pp. 2461–2478, 2015.

[6] A. J. Dirks-Naylor, N. T. K. Tran, S. Yang, R. Mabolo, and S. A. Kouzi, “The effects of acute doxorubicin treatment on proteome lysine acetylation status and apical caspasases in skeletal muscle of fasted animals,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 3, pp. 239–245, 2013.

[7] H. L. Xu, Pharmacology of Traditional Chinese Medicine, pp. 290–291, Shanghai Science and Technology Publishing House, 3rd edition, Shanghai, China, 2019.

[8] X. Li, X. Hu, Y. Li, and D. Yang, “Clinical and experimental research progress of Huangqi Sijunzi decoction and its modified formula,” Research of Traditional Chinese medicine, vol. 34, no. 4, pp. 57–60, 2021.

[9] R. Zhang, X. Zhu, H. Bai, and K. Ning, “Network pharmacology databases for traditional Chinese medicine: review and assessment,” Frontiers in Pharmacology, vol. 10, p. 123, 2019.

[10] J. Wang and X. Li, “Network pharmacology and drug discovery,” Sheng Li Ke Xue Jin Zhan, vol. 42, no. 4, pp. 241–245, 2011.

[11] Y. Jiang, M. Zhong, F. Long, R. Yang, Y. Zhang, and T. Liu, “Network pharmacology-based prediction of active ingredients and mechanisms of Lamiophlomis rotata (Benth.) kudo against rheumatoid arthritis,” Frontiers in Pharmacology, vol. 10, p. 1435, 2019.

[12] Y. Xiong, Y. Yang, W. Xiong, Y. Yao, H. Wu, and M. Zhang, “Network pharmacology-based research on the active component and mechanism of the antihypertension effect of Rubia cordifolia L,” Journal of Cellular Biochemistry, vol. 120, no. 8, pp. 12461–12472, 2019.

[13] Q. Zhang, J. Liu, R. Li et al., “A network pharmacology approach to investigate the anticancer mechanism and potential active ingredients of Rheum palmatum L against lung cancer via induction of apoptosis,” Frontiers in Pharmacology, vol. 11, Article ID 528308, 2020.

[14] H. Shi, S. Tian, and H. Tian, “Network pharmacology interpretation of Fuzheng-jiedu decoction against colorectal cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 4652492, 16 pages, 2021.

[15] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[16] UniProt Consortium, “UniProt: a worldwide hub of protein knowledge,” Nucleic Acids Research, vol. 47, no. D1, pp. D506–D515, 2019.

[17] M. Safran, I. Dalah, J. Alexander et al., “GeneCards version 3: the human gene integrator,” Database, vol. 2010, Article ID baq020, 2010.

[18] NcBi Resource Coordinators, “Database resources of the national center for biotechnology information,” Nucleic Acids Research, vol. 46, no. D1, pp. D8–D13, 2018.

[19] J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, “OMIM.org: online mendelian inheritance in man (OMIM®), an online catalog of human genes and genetic disorders,” Nucleic Acids Research, vol. 43, pp. D789–D798, 2015.

[20] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.

[21] N. T. Doncheva, J. H. Morris, J. Gorodkin, and L. J. Jensen, “Cytoscape stringapp: network analysis and visualization of proteomics data,” Journal of Proteome Research, vol. 18, no. 2, pp. 623–632, 2019.

[22] X. H. Wan, X. M. Chen, S. Ma et al., “Application of the new extraction methods of flavonoids,” Chinese Herbal Medicine, vol. 15, pp. 3691–3699, 2019.

[23] S. Miltonprabu, M. Tomczyk, K. Skalicka-Woźniak et al., “Hepatoprotective effect of quercetin: from chemistry to medicine,” Food and Chemical Toxicology, vol. 108, pp. 365–374, 2017.

[24] N. Ma, Y. J. Li, and J. P. Fan, “Research progression on the pharmacological activity of quercetin,” Journal of Liaoning University of Traditional Chinese Medicine, vol. 20, no. 8, pp. 221–224, 2018.

[25] X. Li, N. Zhou, J. Wang et al., “Quercetin suppresses breast cancer stem cells (CD44+/CD24-) by inhibiting the PI3K/Akt/mTOR-signaling pathway,” Life Sciences, vol. 196, pp. 56–62, 2018.

[26] T.-C. Wu, S.-T. Chan, C.-N. Chang, P.-S. Yu, C.-H. Chuang, and S.-L. Yeh, “Quercetin and chrysine inhibit nickel-induced invasion and migration by downregulation of TLR4/NF-κB signaling in A549 cells,” Chemico-Biological Interactions, vol. 292, pp. 101–109, 2018.

[27] S.-M. Tang, X.-T. Deng, J. Zhou, Q.-P. Li, X.-X. Ge, and L. Miao, “Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects,” Biomedicine & Pharmacotherapy, vol. 121, Article ID 109604, 2020.

[28] D. D. Shi and G. M. Wang, “Mechanism of luteolin in suppressing MCF-7 cells based on cell metabolomics,” Analytical Chemistry, vol. 42, no. 8, pp. 1088–1093, 2014.

[29] L. F. Wang, F. Y. Zhao, and X. E. Tang, “Luteolin induces SW480 colon cancer cell apoptosis via the mitochondrial apoptosis pathway,” Chinese Journal of Clinical Pharmacology, vol. 35, no. 17, pp. 1862–1864, 2019.

[30] J. Y. Mo, S. X. Luo, H. Y. Zhang, L. Zhang, and R. X. Wang, “Antitumor effect of luteolin,” Asia-Pacific Traditional Medicine, vol. 2, pp. 177–181, 2021.

[31] C. Gu, C. C. Wang, Q. F. Xu, W. Liu, and D. D. Hu, “Kaempferol regulates the PI3K/Akt/mTOR pathway to induce human colorectal cancer RKO cells autophagy,” Central South Pharmacy, vol. 10, pp. 1668–1673, 2020.

[32] G. P. Chen, M. Q. Li, and X. H. Ying, “Isohamnetin suppresses lung cancer proliferation and invasion via the mTOR pathway and its mechanism,” Chinese Medicinal Materials, vol. 2, pp. 423–428, 2021.

[33] C. Rodríguez-García, C. Sánchez-Quesada, and J. Gaforio, “ Dietary flavonoids as cancer chemopreventive agents: an updated review of human studies,” Antioxidants, vol. 8, no. 5, p. 137, 2019.

[34] L. Bao, F. Liu, H.-b. Guo et al., “Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway,” Tumor Biology, vol. 37, no. 8, pp. 11365–11374, 2016.

[35] Z. Chu, X. H. Liang, X. L. Zhou, R.-f. Huang, Q. Z. Zhan, and J.-w. Jiang, “Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway,” Journal of Chinese Integrative Medicine, vol. 9, no. 5, pp. 533–538, 2011.

[36] Yi Zhao, UT_three-dimensional Co-Culture Microfluidic Model and its Application on Cancer Research, Chongqing University, Chongqing, China, 2017.

[37] Y. R. Yang, X. L. Zheng, and H. Y. Li, “Relationship of AKT1 expression with the clinicopathological features and prognosis
of non-small cell lung cancer,” *The Practical Journal of Cancer*, vol. 36, no. 3, pp. 364–367, 2021.

[38] Y. F. Wei, S. S. Liu, L. J. Jin, W. J. Chen, Y. N. Lin, and H. Liu, “Research progress of flavonoid monomers of Chinese traditional herbs in suppressing tumor through the PI3K/Akt signaling pathway,” *Chinese Journal of Traditional Chinese Medicine*, vol. 39, no. 10, pp. 6–259, 2021.

[39] X. J. Liu, *Screening and Function of Esophageal Squamous Cell Carcinoma-Related Molecular Targets*, Xinjiang Medical University, Ürümqi, China, 2017.

[40] W. J. Li, Y. H. Chen, and N. Wang, “Mechanism of curcumin in affecting the c-Jun and JAK-STAT signaling pathways in cervical cancer cell line,” *Journal of Guangxi Medical University*, vol. 37, no. 2, pp. 213–218, 2020.

[41] J. Sun, D. G. Zhao, M. Y. Wang, F. M. Zhao, D. Q. Xu, and L. H. Ye, “Effect of quercetin on the PI3K/AKT signaling pathway in SMMC-7721 liver cancer cells,” *Chinese Journal of Experimental Formulae*, vol. 18, no. 18, pp. 223–226, 2012.

[42] X. F. Jia, W. M. Chen, D. P. Sun et al., “Research on quercetin in suppressing epithelial-mesenchymal transition in gastric cancer,” *Journal of Hainan Medical College*, vol. 21, no. 8, pp. 1030–1032, 2015.

[43] Y. L. Guan, G. Q. Qu, and H. M. Jiang, “Effect of quercetin on the proliferation and apoptosis of kidney cancer 786-0 cells and its mechanism,” *Shandong Medical Journal*, vol. 52, no. 18, pp. 30-31, 2012.

[44] Y. Zhang, *Luteolin Affects the Proliferation, Apoptosis and Metastasis of Human Tongue Squamous Carcinoma Tca8113 Cells through the PI3K-Akt-NF-κb Signaling Pathway*, Lanzhou University, Gansu Sheng, China, 2017.

[45] Y. Zhao, *Experimental Research of miR-433 Targets Promoting Apoptosis and Inhibiting the Proliferation and Migration in Gastric Cancer Cells Targeting JNK1*, Tianjin Medical University, Tianjin, China, 2019.

[46] D. Wu, *Exploring the Mechanism of Th17 Differentiation and Treatment of Traditional Chinese Medicine in Ankylosing Spondylitis through TAZ Regulated by Hippo Signaling Pathway*, Chinese Academy of Traditional Chinese Medicine, Beijing, China, 2020.

[47] H. Sekizawa, K. Ikuta, M. Ohnishi-Kameyama, K. Nishiya, and T. Suzutani, “Identification of the components in a Vaccinium oldhamii extract showing inhibitory activity against influenza virus adsorption,” *Foods*, vol. 8, no. 5, p. 172, 2019.